BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing

Reuters01-01

Dec 31 (Reuters) - Climb Bio Inc CLYM.O:

CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILING
CLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024
CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT "PRODUCT" UNDER APA
CLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG

Source text: [ID:n0001193125-25-338318]

Further company coverage: CLYM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600731704?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-01 06:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600731704","market":"nz","top_or_hot":-1,"title":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing</title></head><body><p><span>Dec 31 (Reuters)</span><span> - </span>Climb Bio Inc <span>CLYM.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/CLYM\">CLIMB BIO INC</a> - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILING</p></li><li><p>CLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024</p></li><li><p>CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT \"PRODUCT\" UNDER APA</p></li><li><p>CLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG</p></li></ul><p>Source text: [ID:n0001193125-25-338318]</p><p>Further company coverage: <span>CLYM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-01 06:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing</title></head><body><p><span>Dec 31 (Reuters)</span><span> - </span>Climb Bio Inc <span>CLYM.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/CLYM\">CLIMB BIO INC</a> - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILING</p></li><li><p>CLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024</p></li><li><p>CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT \"PRODUCT\" UNDER APA</p></li><li><p>CLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG</p></li></ul><p>Source text: [ID:n0001193125-25-338318]</p><p>Further company coverage: <span>CLYM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLYM","symbol_name":"CLIMB BIO INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:1","article_id":"2600731704","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600731704","pubTimestamp":1767220603,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC FilingDec 31  - Climb Bio Inc CLYM.O:CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILINGCLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT \"PRODUCT\" UNDER APACLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUGSource text: [ID:n0001193125-25-338318]Further company coverage: CLYM.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLYM":"CLIMB BIO INC","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"BRIEF-Climb Bio对Alumis和Acelyrin提出投诉-SEC备案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9},"content_text":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC FilingDec 31 (Reuters) - Climb Bio Inc CLYM.O:CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILINGCLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT \"PRODUCT\" UNDER APACLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUGSource text: [ID:n0001193125-25-338318]Further company coverage: CLYM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600731704","isCrawlerRequest":true}